Eli Lilly and Company (NYSE:LLY) stock is moving lower on Thursday on possible continued weakness after recent weight loss data from Roche.

What To Know: On Wednesday, Roche announced positive Phase I data from its clinical trial in regards to CT-996, a once-daily oral pharmaceutical being developed for the treatment of both type 2 diabetes and obesity.

The data showed a clinically meaningful weight loss of -7.3% and placebo adjusted weight loss of -6.1% following four weeks of treatment. The trial contained participants with obesity but not type 2 diabetes.

The novel treatment was generally well tolerated with mostly mild or moderate gastrointestinal-related adverse events. In addition, the recent data release from Roche may cause competition concerns for companies in the weight loss market.

How To Buy Eli Lilly and Company Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Eli Lilly and Co (NYSE:LLY)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Related Link: Justice Dept. Argues Medical Marijuana Users Owning Guns Pose Public Safety Risk In Florida Case

LLY Price Action: As of Thursday morning, Eli Lilly and Company shares are trading 6.39% lower at $847.73 per data from Benzinga Pro.

Image: Photo by rafapress on Shutterstock